Straits Times Index
3,187.17 +32.48 (+1.03%) Nikkei
38,090.87 +129.07 (+0.34%) Hang Seng
16,493.39 +241.55 (+1.49%) FTSE 100
7,847.99 +27.63 (+0.35%) Bitcoin USD
61,682.20 -2,161.08 (-3.38%) CMC Crypto 200
885.54 0.00 (0.00%)
Tonix Pharmaceuticals Holding Corp. (TNXP)
After hours:
| Previous close | 0.1499 |
| Open | 0.1550 |
| Bid | 0.1000 x 1400 |
| Ask | 0.1800 x 300 |
| Day's range | 0.1459 - 0.1600 |
| 52-week range | 0.1200 - 3.3125 |
| Volume | |
| Avg. volume | 2,196,170 |
| Market cap | 15.23M |
| Beta (5Y monthly) | 2.23 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.8500 |
| Earnings date | 06 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.50 |
GlobeNewswireTonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Positive results from confirmatory Phase 3 RESILIENT study reported in December 2023 position Tonmya™ for fibromyalgia for NDA submission second half of 2024; pre-NDA meeting with FDA scheduled for second quarter 2024 Commercial planning underway, including go-to-market, supply chain and manufacturing strategies, for U.S. launch of Tonmya, a potential new first-line, centrally-acting, non-opioid analgesic for the management of fibromyalgia CHATHAM, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Tonix
- GlobeNewswire
Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering
CHATHAM, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical company, today announced it has entered into a securities purchase agreement with existing healthcare focused institutional investors of the Company for the purchase and sale of 14,666,666 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 14,666,666 shares of common stock in a reg
- GlobeNewswire
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome
TNX-2900 is a proprietary magnesium-potentiated formulation of intranasal oxytocin, a naturally occurring hormone that reduces appetite and eating Prader Willi syndrome is the most common genetic cause of life-threatening childhood obesity CHATHAM, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the U.S. Food and Drug Adm
